

Hematological quick reference chart^{1†}

How CSAN[®] defines results associated with ANC[‡] laboratory values

Green (normal values for clozapine treatment)	
<ul style="list-style-type: none">ANC $\geq 2.0 \times 10^9/L$	<ul style="list-style-type: none">Continue to dispense CLOZARIL[®]Monitor as follows for eligible patients:[§]<ul style="list-style-type: none">Weekly for the first 26 weeksEvery 2 weeks for the next 26 weeksEvery 4 weeks as of 52 weeks
Yellow Alert(s)	
<p>ANC in the range of:</p> <ul style="list-style-type: none">$1.5 \times 10^9/L \leq \text{ANC} < 2.0 \times 10^9/L$	<ul style="list-style-type: none">Hematological monitoring at least twice a week until absolute neutrophil count (ANC) stabilize or increaseContinue to dispense CLOZARIL[®]
Red Alert(s)	
<ul style="list-style-type: none">ANC $< 1.5 \times 10^9/L$ <p>Consider protective isolation when:</p> <ul style="list-style-type: none">ANC $< 0.5 \times 10^9/L$ <p>Should evidence of infection develop, appropriate cultures should be performed, and an appropriate antibiotic regimen be instituted.</p>	<p>Immediately withhold CLOZARIL[®] and monitor patient closely.</p> <p>Confirmation of the haematological values is recommended within 24 h.</p> <p>Stop CLOZARIL[®] therapy immediately if results are confirmed.</p> <p>Blood monitoring should occur at least weekly following discontinuation of CLOZARIL[®] therapy until ANC is $\geq 2.0 \times 10^9/L$, irrespective of the cause of discontinuation.</p> <p>Particular attention should be paid to any flu-like complaints or other symptoms which might suggest infection (i.e. fever, sore throat, or any other signs of infection).</p> <p>CLOZARIL[®] therapy must not be resumed.</p> <p>A Non-rechallengeable status is immediately assigned to the patient's profile.</p> <p>Consult with a CSAN[®] hematologist.</p>

Consider hematology consultation before initiating or during CLOZARIL[®] treatment as necessary.

For any additional information regarding CLOZARIL[®] hematological guidelines, Benign Ethnic Neutropenia (BEN) Guidelines, or Special Case Guidelines please reach out to CSAN[®] at 1-800-267-2726

Questions?

Don't hesitate to contact us:

CSAN[®]



Phone: 1-800-267-2726



Fax: 1-800-465-1312

[†] Please consult the prescribing information for complete hematological monitoring information.

[‡] ANC=Absolute Neutrophil Count; Neutropenia

[§] The change from a weekly to a "once every two weeks" or from "once every two weeks" to a "once every four weeks" schedule should be based upon the hematological profile of the patient as well as the clinical judgement of the treating physician, and if deemed appropriate, a consulting hematologist and on the patient's willingness to pursue a given frequency of blood monitoring. The clinical evaluation should take into consideration possible factors that would place the patient in a higher risk group.

CLOZARIL® (clozapine) tablet is indicated in the management of symptoms of treatment-resistant schizophrenia.

Please consult the CLOZARIL® Product Monograph at clozaril.ca/clozaril_monograph for important information about:

- Contraindications in patients with myeloproliferative disorders, active liver disease, severe central nervous system depression or comatose states, severe renal or cardiac disease (e.g., myocarditis), paralytic ileus, uncontrolled epilepsy, and others.
- Serious warnings and precautions regarding severe neutropenia (agranulocytosis), myocarditis and cardiomyopathy and mitral valve incompetence, and increased mortality in elderly patients with dementia.
- Conditions of clinical use, adverse reactions, drug interactions and dosing instructions.

The Product Monograph is also available by calling 1-800-267-2726.

ANC=Absolute Neutrophil Count;
Please note: All cell counts are expressed in units of $10^9/L$.

Reference:
1. CLOZARIL® Product Monograph, HLS Therapeutics Inc. May 31st 2021.

CA-CL-00022-EN



HLS Therapeutics Inc.
10 Carlson Court, Suite 701
Etobicoke, Ontario M9W 6L2
www.hlstherapeutics.com



CLOZARIL, CSAN and CSAN Patient Care Portal + Design are all registered trademarks of Novartis AG.
© Copyright 2022 HLS Therapeutics Inc.
February 2022

